» Articles » PMID: 19535450

A Patch of Positively Charged Amino Acids Surrounding the Human Immunodeficiency Virus Type 1 Vif SLVx4Yx9Y Motif Influences Its Interaction with APOBEC3G

Overview
Journal J Virol
Date 2009 Jun 19
PMID 19535450
Citations 70
Authors
Affiliations
Soon will be listed here.
Abstract

The amino-terminal region of the Vif molecule in human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus (SIV) contains a conserved SLV/Ix4Yx9Y motif that was first described in 1992, but the importance of this motif for Vif function has not yet been examined. Our characterization of the amino acids surrounding this motif in HIV-1 Vif indicated that the region is critical for APOBEC3 suppression. In particular, amino acids K22, K26, Y30, and Y40 were found to be important for the Vif-induced degradation and suppression of cellular APOBEC3G (A3G). However, mutation of these residues had little effect on the Vif-mediated suppression of A3F, A3C, or A3DE, suggesting that these four residues are not important for Vif assembly with the Cul5 E3 ubiquitin ligase or protein folding in general. The LV portion of the Vif SLV/Ix4Yx9Y motif was found to be required for optimal suppression of A3F, A3C, or A3DE. Thus, the SLV/Ix4Yx9Y motif and surrounding amino acids represent an important functional domain in the Vif-mediated defense against APOBEC3. In particular, the positively charged K26 of HIV-1 Vif is invariably conserved within the SLV/Ix4Yx9Y motif of HIV/SIV Vif molecules and was the most critical residue for A3G inactivation. A patch of positively charged and hydrophilic residues (K(22)x(3)K(26)x(3)Y(30)x(9)YRHHY(44)) and a cluster of hydrophobic residues (V(55)xIPLx(4-5)LxPhix2YWxL(72)) were both involved in A3G binding and inactivation. These structural motifs in HIV-1 Vif represent attractive targets for the development of lead inhibitors to combat HIV infection.

Citing Articles

HIV-1 Vif global diversity and possible APOBEC-mediated response since 1980.

Lewitus E, Li Y, Rolland M Virus Evol. 2025; 11(1):veae108.

PMID: 39886100 PMC: 11781276. DOI: 10.1093/ve/veae108.


Direct inhibition of human APOBEC3 deaminases by HIV-1 Vif independent of the proteolysis pathway.

Kamba K, Wan L, Unzai S, Morishita R, Takaori-Kondo A, Nagata T Biophys J. 2023; 123(3):294-306.

PMID: 38115583 PMC: 10870137. DOI: 10.1016/j.bpj.2023.12.015.


HIV-1 Vif protein sequence variations in South African people living with HIV and their influence on Vif-APOBEC3G interaction.

Williams M Eur J Clin Microbiol Infect Dis. 2023; 43(2):325-338.

PMID: 38072879 PMC: 10821834. DOI: 10.1007/s10096-023-04728-0.


Mammalian Genomic Manipulation with Orthogonal Bxb1 DNA Recombinase Sites for the Functional Characterization of Protein Variants.

Roelle S, Kamath N, Matreyek K ACS Synth Biol. 2023; 12(11):3352-3365.

PMID: 37922210 PMC: 10661055. DOI: 10.1021/acssynbio.3c00355.


Structural insights into RNA bridging between HIV-1 Vif and antiviral factor APOBEC3G.

Kouno T, Shibata S, Shigematsu M, Hyun J, Kim T, Matsuo H Nat Commun. 2023; 14(1):4037.

PMID: 37419875 PMC: 10328928. DOI: 10.1038/s41467-023-39796-5.


References
1.
Bogerd H, Cullen B . Single-stranded RNA facilitates nucleocapsid: APOBEC3G complex formation. RNA. 2008; 14(6):1228-36. PMC: 2390788. DOI: 10.1261/rna.964708. View

2.
Luo K, Liu B, Xiao Z, Yu Y, Yu X, Gorelick R . Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging. J Virol. 2004; 78(21):11841-52. PMC: 523292. DOI: 10.1128/JVI.78.21.11841-11852.2004. View

3.
Mbisa J, Barr R, Thomas J, Vandegraaff N, Dorweiler I, Svarovskaia E . Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. J Virol. 2007; 81(13):7099-110. PMC: 1933301. DOI: 10.1128/JVI.00272-07. View

4.
Miyagi E, Opi S, Takeuchi H, Khan M, Goila-Gaur R, Kao S . Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1. J Virol. 2007; 81(24):13346-53. PMC: 2168852. DOI: 10.1128/JVI.01361-07. View

5.
Lecossier D, Bouchonnet F, Clavel F, Hance A . Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science. 2003; 300(5622):1112. DOI: 10.1126/science.1083338. View